Corvus Pharmaceuticals released interim Phase 1 clinical trial data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe atopic dermatitis. The 28-day results from cohort 3 (400mg total daily dose) show earlier and more significant improvements compared to cohorts 1 and 2 (200mg total daily dose), and all three cohorts demonstrated statistically significant improvement over placebo. Notably, cohort 3 showed a clinically meaningful itch reduction as early as day 8.
This data is important because it suggests soquelitinib could offer a faster-acting treatment for atopic dermatitis, particularly addressing the often-debilitating symptom of itch. The significant improvement observed with the higher dose in cohort 3 may guide future dosing strategies for greater efficacy. This could lead to improved quality of life for patients suffering from this chronic condition.
Cohort 3 participants, who had more severe baseline atopic dermatitis, showed a 64.8% mean reduction in EASI score at 28 days, compared to 54.6% for the combined cohorts 1 and 2, and 34.4% for the placebo group. Furthermore, 50% of cohort 3 patients experienced a clinically meaningful reduction in itch by day 28. The drug continues to be well-tolerated, with no dose-limiting toxicities or serious adverse events observed. Corvus has initiated an extension cohort study exploring the 400mg daily dose of soquelitinib over a longer 8-week treatment period.
The positive interim data reinforces the potential of soquelitinib as a safe and effective treatment for atopic dermatitis. The extended study will provide valuable information about the drug’s long-term efficacy and safety, potentially paving the way for larger-scale trials and eventual regulatory approval. This could position soquelitinib as a valuable new therapeutic option in the atopic dermatitis treatment landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
